Pharma turns cold shoulder to UK

Roche and Merck Serono recently sized up their chances to pass muster with the UK's cost-effectiveness regulators and decided to give NICE a pass. Analysts say that the clinical- and cost-effectiveness evaluators at NICE have been turning an increasingly skeptical eye on some of the expensive biologics coming their way. And that helped persuade both big pharma companies to forget about making full submissions to NICE on Avastin and Erbitux. Article

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.